The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The values for body composition and lean mass of the controls are within the ranges previously published for non-athletic but otherwise healthy older adults from larger, multi-center studies (Bijlsma et al., 2013; Bauer et al., 2015; Coulson et al., 2017; Verlaan et al., 2017).”
From Comparison of Muscle Function, Bone Mineral Density and Body Composition of Early Starting and Later Starting Older Masters Athletes (2019) · cites this paper as Coulson et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism
Ferron, M., Wei, J., Yoshizawa, T., Del Fattore, A., DePinho, R. A., Teti, A., Ducy, P., & Karsenty, G. (2010) · Cell · doi:10.1016/j.cell.2010.06.003 · Cited by 1,123 · cited 2×
“Osteocalcin (OC) is a major non-collagen protein of the bone matrix secreted by osteoblasts for bone formation, but released from the matrix during bone resorption [3].”
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 3×
“It has been shown to protect against generalised bone resorption by blocking tumour necrosis factor alpha, (TNFα), in models of chronic inflammation [18] and is considered to be a decoy receptor for RANKL to reduce osteoclast-driven bone resorption [19].”
Rogers, A., Saleh, G., Hannon, R. A., Greenfield, D., & Eastell, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020396 · Cited by 200
Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Görtz, B., Schulz, A., Bergmeister, H., Kollias, G., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11150 · Cited by 150
Oh, K. W., Rhee, E. J., Lee, W. Y., Kim, S. W., Baek, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Ihm, S. H., Choi, M. G., et al. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02179.x · Cited by 73
Research works printed but not linked: 27
- Genant HK et al (1999) Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporos Int 10(4):259–264 · DOI · Paper page
- Kamiya N (2012) The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Curr Mol Pharmacol 5(2):153–163 · DOI
- Gaudio A et al (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95(5):2248–2253 · DOI · Paper page
- Ke HZ et al (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr rev 33(5):747–783 · DOI · Paper page
- Takei Y, Minamizaki T, Yoshiko Y (2015) Functional diversity of fibroblast growth factors in bone formation. Int J Endocrinol 2015:729352 · DOI
- Standal T, Borset M, Sundan A (2004) Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26(3):179–184
- McPhee JS et al (2013) Physiological and functional evaluation of healthy young and older men and women: design of the European MyoAge study. Biogerontology 14(3):325–337 · DOI
- Monroe DG et al (2012) Update on Wnt signaling in bone cell biology and bone disease. Gene 492(1):1–18 · DOI · Paper page
- Brunetti G et al (2016) Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-alpha. Osteoporos Int 27(7):2355–2365 · DOI
- Roforth MM et al (2014) Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone 59:1–6 · DOI
- Butler JS et al (2011) The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density. J Orthop res 29(3):414–418 · DOI
- Szulc P et al (2013) Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J Bone Miner res 28(8):1760–1770 · DOI
- Garnero P et al (2013) Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 24(2):489–494 · DOI
- Polyzos SA et al (2012) Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide. Osteoporos Int 23(3):1171–1176 · DOI
- Thorson S et al (2013) Sclerostin and bone strength in women in their 10th decade of life. J Bone Miner res 28(9):2008–2016 · DOI
- Weitzmann MN (2013) The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo) 2013:125705
- Jabbar S et al (2011) Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol 64(4):354–357 · DOI
- Liu JM et al (2005) Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20–75. Calcif Tissue Int 76(1):1–6 · DOI
- Samelson EJ et al (2008) Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. J Clin Endocrinol Metab 93(5):1789–1795 · DOI
- Stern A et al (2007) The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 156(5):555–562 · DOI
- Modder UI et al (2011) Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner res 26(1):27–34 · DOI · Paper page
- Modder UI et al (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner res 26(2):373–379 · DOI · Paper page
- Mazziotti G et al (2006) Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. Eur J Endocrinol 154(3):373–377 · DOI
- Moester MJ et al (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87(2):99–107 · DOI · Paper page
- Atalay S et al (2012) Diagnostic utility of osteocalcin, undercarboxylated osteocalcin, and alkaline phosphatase for osteoporosis in premenopausal and postmenopausal women. Ann lab med 32(1):23–30 · DOI
- Mora S et al (2015) Sclerostin and DKK-1: two important regulators of bone metabolism in HIV-infected youths. Endocrine 49(3):783–790 · DOI
- Fan B et al (2010) Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems? Osteoporos Int 21(7):1227–1236 · DOI
Cited by
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519
Piasecki, J., Ireland, A., Piasecki, M., Deere, K., Hannam, K., Tobias, J., & McPhee, J. S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01050 · Cited by 24
Self-citation
Metadata
- Authors
- Coulson, J., Bagley, L., Barnouin, Y., Bradburn, S., Butler-Browne, G., Gapeyeva, H., Hogrel, J.-Y., Maden-Wilkinson, T., Maier, A. B., Meskers, C., Murgatroyd, C., Narici, M., Pääsuke, M., Sassano, L., Sipilä, S., AL-Shanti, N., Stenroth, L., Jones, D. A., & McPhee, J. S.
- Venue
- Osteoporosis International
- Published
- 2017-06-05
- Volume
- 28
- Issue
- 9
- Pages
- 2683-2689
- ISSN
- 0937-941X
- 1433-2965
- Cited by
- 37
- References
- 5
- Language
- en
- Funders
- European Union (FP7 MYOAGE 223576)
- Medical Research Council (MR/K025252/1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
